• About
  • Policies
  • What is open access
  • Library
  • Contact
Advanced search
      View Item 
      •   BUIR Home
      • Scholarly Publications
      • Faculty of Science
      • Department of Molecular Biology and Genetics
      • View Item
      •   BUIR Home
      • Scholarly Publications
      • Faculty of Science
      • Department of Molecular Biology and Genetics
      • View Item
      JavaScript is disabled for your browser. Some features of this site may not work without it.

      Dominant B-cell epitopes from cancer / stem cell antigen SOC2 recognized by serum samples from cancer patients

      Thumbnail
      View / Download
      1.1 Mb
      Author(s)
      Shih, J.
      Rahman, M.
      Luong, Q. T.
      Lomeli, S. H.
      Riss, J.
      Prins, R. M.
      Gure, A. O.
      Zeng, G.
      Date
      2014-08-30
      Source Title
      American Journal of Clinical and Experimental Immunology
      Print ISSN
      2164-7712
      Publisher
      AJCEI
      Volume
      3
      Issue
      2
      Pages
      84 - 90
      Language
      English
      Type
      Article
      Item Usage Stats
      62
      views
      16
      downloads
      Abstract
      Human sex determining region Y-box 2 (SOX2) is an important transcriptional factor involved in the pluripotency and stemness of human embryonic stem cells. SOX2 plays important roles in maintaining cancer stem cell activities of melanoma and cancers of the brain, prostate, breast, and lung. SOX2 is also a lineage survival oncogene for squamous cell carcinoma of the lung and esophagus. Spontaneous cellular and humoral immune responses against SOX2 present in cancer patients classify it as a tumor-associated antigen (TAA) shared by lung cancer, glioblastoma, and prostate cancer among others. In this study, B-cell epitopes were predicted using computer-assisted algorithms. Synthetic peptides based on the prediction were screened for recognition by serum samples from cancer patients using ELISA. Two dominant B-cell epitopes, SOX2:52-87 and SOX2:98-124 were identified. Prostate cancer, glioblastoma and lung cancer serum samples that recognized the above SOX2 epitopes also recognized the full-length protein based on Western blot. These B-cell epitopes may be used in assessing humoral immune responses against SOX2 in cancer immunotherapy and stem cell-related transplantation.
      Keywords
      Ips Cell
      Pluripotent Stem Cell
      Cancer Stem Cell
      Autoantibody
      Biomarkers
      Permalink
      http://hdl.handle.net/11693/12803
      Collections
      • Department of Molecular Biology and Genetics 468
      Show full item record

      Browse

      All of BUIRCommunities & CollectionsTitlesAuthorsAdvisorsBy Issue DateKeywordsTypeDepartmentsThis CollectionTitlesAuthorsAdvisorsBy Issue DateKeywordsTypeDepartments

      My Account

      LoginRegister

      Statistics

      View Usage StatisticsView Google Analytics Statistics

      Bilkent University

      If you have trouble accessing this page and need to request an alternate format, contact the site administrator. Phone: (312) 290 1771
      © Bilkent University - Library IT

      Contact Us | Send Feedback | Off-Campus Access | Admin | Privacy